On October 11th, the official website of the National Medical Products Administration showed that the market application for junshi bio's recombinant humanized anti-PCSK9 monoclonal antibody evolocumab injection (JS002, trade name: Shushi Da) has been approved. Indications: On the basis of controlling diet, in combination with statins, or in combination with statins and ezetimibe, used in adult patients with primary hypercholesterolemia (non-familial) and mixed dyslipidemia who are receiving moderate or higher doses of statins and still cannot achieve the target low-density lipoprotein cholesterol (LDL-C) levels.